Operating through 126 Company-operated treatment centers, Greenbrook is a leading provider of Transcranial Magnetic Stimulation (“TMS”) therapy, an FDA-cleared, non-invasive therapy for the treatment of Major Depressive Disorder and other mental health disorders, in the United States. TMS therapy provides local electromagnetic stimulation to specific brain regions known to be directly associated with mood regulation. Greenbrook has provided more than 510,000 TMS treatments to over 14,000 patients struggling with depression.
This company cross-lists their shares on a U.S. stock exchange. See the related U.S. symbol GBNH.
This company has cross-listed shares that trade in the U.S. as the symbol GBNH.
2.96 CAD
As of 02/03/2023
2022 © Stock Market MBA, Inc.